OmniAb (OABI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
Annual meeting scheduled for June 17, 2026, at 8:00 AM PT in Emeryville, CA.
Proxy materials and 2025 Annual Report are available online for review and voting.
Shareholders are encouraged to vote electronically or request paper materials by June 6, 2026.
Voting matters and shareholder proposals
Election of two directors: Matthew W. Foehr and Jennifer Cochran, Ph.D.
Ratification of Ernst & Young LLP as the independent registered public accounting firm.
Board recommends voting FOR all nominees and FOR the auditor ratification.
Board of directors and corporate governance
Board has nominated two individuals for election to the board.
Partial view of Summaries dataset, powered by Quartr API
Latest events from OmniAb
- A 425-program antibody platform pairs licensing economics with a scaling screening-instrument business.OABI
LD Micro 20th Annual Main Event Conference - A maturing royalty pipeline and xPloration and OmniTides expansion broaden growth opportunities.OABI
Investor And Anlayst Day 2026 - Q2 2026 delivered strong revenue growth, clinical pipeline expansion, and new technology launches.OABI
Corporate presentation - Q2 2026 revenue jumped, net loss narrowed, and guidance was raised amid strong partner momentum.OABI
Q2 2026 - Innovative antibody discovery platform drives partner growth, clinical pipeline, and long-term royalties.OABI
Jefferies Global Healthcare Conference - Q1 2026 revenue soared 247% to $14.4M, net loss narrowed, and guidance was raised.OABI
Q1 2026 - Annual meeting to elect directors and ratify auditor, with strong governance and ESG focus.OABI
Proxy filing - Q2 revenue rose to $7.6M, net loss narrowed, and new partnerships support future growth.OABI
Q2 2024 - Q1 2025 revenue rose 10.5% with new tech launches, narrowed loss, and guidance affirmed.OABI
Q1 2025